ArticleJournal of clinical medicine2021
Comparison of Indexes to Measure Comorbidity Burden and Predict All-Cause Mortality in Rheumatoid Arthritis.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Predicting All-Cause Mortality Using Two Claims-Based Measures in Medicare Beneficiaries With Dementia.Medical care research and review : MCRR · 2026Article
- Charleson and Elixhauser Comorbidity Indices in Predicting Mortality Among Young and Old Cervical Cancer Patients.Cancer medicine · 2026Article
- Multimorbidity measurement strategies for predicting hospital visits.BMC health services research · 2025Article
- Integrating Multimorbidity Assessment into Rheumatology Care: Prognostic Role of the Charlson Comorbidity Index in Systemic Lupus Erythematosus.Healthcare (Basel, Switzerland) · 2025Review
- Longitudinal Assessment of Body Composition and Inflammatory Status in Rheumatoid Arthritis During TNF Inhibitor Treatment: A Pilot Study.International journal of molecular sciences · 2025Observational
- Multimorbidity and COVID-19 Outcomes in the Emergency Department: Is the Association Mediated by the Severity of the Condition at Admission?Journal of clinical medicine · 2024Article
- Article
- A Real-World Study on the Clinical Characteristics, Outcomes, and Relationship between Antibiotic Exposure andAntibiotics (Basel, Switzerland) · 2024Article
- Multimorbidity in Rheumatoid Arthritis: Literature Review and Future Directions.Current rheumatology reports · 2024Review
- Clinical Features Associated With Rate of Fractures in Patients With Systemic Sclerosis: A US Cohort Study.Arthritis care & research · 2023Article
- Viewpoint: how to measure comorbidities in patients with rheumatoid arthritis - clinical and academic value.Rheumatology (Oxford, England) · 2023Article
- PDCD5 as a Potential Biomarker for Improved Prediction of the Incidence and Remission for Patients with Rheumatoid Arthritis.Rheumatology and therapy · 2023Article
- Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar.Archives of rheumatology · 2023Article
- Association between Rheumatic Disease Comorbidity Index and factors of poor prognosis in a cohort of 280 patients with rheumatoid arthritis.BMC rheumatology · 2022Article
- Association Between Mental Health Conditions and Outpatient Care Fragmentation: a National Study of Older High-Risk Veterans.Journal of general internal medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectivesTo examine the comorbidity burden in patients with rheumatoid arthritis (RA) patients using a nationwide population-based cohort by assessing the Charlson Comorbidity Index (CCI), Elixhauser Comorbidity Index (ECI), Multimorbidity Index (MMI), and Rheumatic Disease Comorbidity Index (RDCI) scores and to investigate their predictive ability for all-cause mortality.
methodsWe identified 24,767 RA patients diagnosed from 1998 to 2008 in Taiwan and followed up until 31 December 2013. The incidence of comorbidities was estimated in three periods (before, during, and after the diagnostic period). The incidence rate ratios were calculated by comparing during vs. before and after vs. before the diagnostic period. One- and 5-year mortality rates were calculated and discriminated by low and high-score groups and modified models for each index.
resultsThe mean score at diagnosis was 0.8 in CCI, 2.8 in ECI, 0.7 in MMI, and 1.3 in RDCI, and annual percentage changes are 11.0%, 11.3%, 9.7%, and 6.8%, respectively. The incidence of any increase in the comorbidity index was significantly higher in the periods of "during" and "after" the RA diagnosis (incidence rate ratios for different indexes: 1.33-2.77). The mortality rate significantly differed between the high and low-score groups measured by each index (adjusted hazard ratios: 2.5-4.3 for different indexes). CCI was slightly better in the prediction of 1- and 5-year mortality rates.
conclusionsComorbidities are common before and after RA diagnosis, and the rate of accumulation accelerates after RA diagnosis. All four comorbidity indexes are useful to measure the temporal changes and to predict mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.